Cancer has long been viewed as a genetic disease of cumulative mutations. This notion is
fuelled by studies showing that ageing tissues are often riddled with clones of complex …

Non-genetic mechanisms have recently emerged as important drivers of anticancer drug
resistance. Among these, the drug tolerant persister (DTP) cell phenotype is attracting more …

Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation
and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors …

The desmoplastic stroma in solid tumors presents a formidable challenge to
immunotherapies that rely on endogenous or adoptively transferred T cells, however, the …

The efficacy of immunotherapy is limited by the paucity of T cells delivered and infiltrated into
the tumors through aberrant tumor vasculature. Here, we report that phosphoglycerate …

Pancreatic ductal adenocarcinoma (PDAC) represents a challenge in oncology, with limited
treatment options for advanced-stage patients. Chimeric antigen receptor T cell (CAR T) …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor
immune microenvironment (TIME) formed by interactions among cancer cells, immune cells …

Programmed cell death protein 1 (PD-1) inhibitors are the most common immune-checkpoint
inhibitors and considered promising drugs for hepatocellular carcinoma (HCC). However, in …

Metabolic reprogramming provides tumors with an energy source and biofuel to support
their survival in the malignant microenvironment. Extensive research into the intrinsic …

The integrated stress response (ISR) refers to signaling pathways initiated by stress-
activated eIF2α kinases. Distinct eIF2α kinases respond to different stress signals, including …